LIANY

Lianbio

A biopharmaceutical company that acted as a bridge for Western drugmakers wanting to enter China, in-licensing experimental medicines from partners like Pfizer and BridgeBio and running their clinical trials in Asia across oncology, heart disease, and eye care. Founded in 2019 by the American investment firm Perceptive Advisors, it took its name from the Chinese character "lián," meaning "to link" or "to connect" — a nod to its mission of linking global innovation with the Chinese market. In 2024 it wound down its drug business and later merged into LianMedical, a medical-device company starting with heart-failure treatments.

ADRUnderlying: LIANYCUSIP: 53000N108HealthcareCN1 holder

Sponsored ADR — Delisted from Nasdaq, shut down operations in 2024

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 3 years

Edelman Joseph +2 co-filersDirector, 10% owner · 4 transactions

32.22M—

as of Feb 2024

Granted 72.6K

Gianakakos AnastasiosDirector · 2 transactions

382.5K+10.6%

as of Feb 2024

Granted 36.3K

Poukalov KonstantinDirector · 2 transactions

36.3K—

as of Feb 2024

Granted 36.3K

Silbermann Susan MicheleDirector · 2 transactions

36.3K—

as of Feb 2024

Granted 36.3K

Stone Adam LeoInterim CEO, Director · 2 transactions

17.1K—

as of Feb 2024

Granted 36.3K

Gu EhongInterim CFO · 2 transactions

0—

as of Apr 2024

Sold 1.7K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Edelman Joseph +2 co-filersDirector, 10% owner · 4 transactions	—	32.22Mas of Feb 2024	72.6K	—	—
Gianakakos AnastasiosDirector · 2 transactions	+10.6%	382.5Kas of Feb 2024	36.3K	—	—
Poukalov KonstantinDirector · 2 transactions	—	36.3Kas of Feb 2024	36.3K	—	—
Silbermann Susan MicheleDirector · 2 transactions	—	36.3Kas of Feb 2024	36.3K	—	—
Stone Adam LeoInterim CEO, Director · 2 transactions	—	17.1Kas of Feb 2024	36.3K	—	—
Gu EhongInterim CFO · 2 transactions	—	0as of Apr 2024	—	—	1.7K

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.